Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EMA teams up with influencers on weight loss drugs

Written by | 6 Dec 2025

The EU drug watchdog, the European Medicines Agency (EMA), has launched a partnership with social media influencers to promote the safe use of GLP-1 receptor agonists. The #HealthNotHype… read more.

GLP-1 agonists: Addressing side effects of weight loss drugs

Written by | 24 Nov 2025

New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at… read more.

Half of people stop taking popular weight-loss drug within a year, national study finds

Written by | 20 Sep 2025

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at… read more.

GLP-1 weight-loss drugs pose hidden risks for young women

Written by | 17 Sep 2025

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. A new study has… read more.

One in seven bariatric surgery patients turn to new weight loss drugs

Written by | 31 Aug 2025

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like… read more.

Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests

Written by | 28 May 2025

Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress… read more.

What’s the mechanism behind behavioral side effects of popular weight loss drugs?

Written by | 25 Jan 2025

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have… read more.

Despite heavy marketing, most Americans reject the new weight-loss drugs

Written by | 10 Oct 2024

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.